ArticleACS applied materials & interfaces2025
Tumor-Embedded Nerve Surgery Using Dual-Channel Intraoperative Imaging Probes.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
During cancer surgery, the identification of normal structures such as nerves is difficult owing to anatomical shifts around the tumor, which increases the risk of nerve injury. Accidental nerve damage can lead to severe complications, including chronic pain, numbness, motor dysfunction, aspiration, and respiratory difficulties. Therefore, precise nerve identification and preservation are critical, even when nerves are located near the tumor. Current nerve-targeted fluorescent contrast agents designed for intravenous administration pose potential risks of systemic side effects. To address this, we developed nerve-specific near-infrared (NIR) fluorophores, including NTFP700, for local application at a wavelength of 700 nm and evaluated its ability to selectively image nerves. Additionally, we explored a dual-channel NIR imaging approach by combining NTFP700 with a tumor-targeted contrast agent (cRGD-ZW800-PEG, 800 nm) to enable clear differentiation of nerves and tumors. NTFP700 effectively highlighted nerve structures with strong fluorescence signals, and its application using a dyed-gauze method allowed for improved visualization, particularly in anatomically altered nerve structures. When combined with cRGD-ZW800-PEG, dual-channel NIR imaging successfully distinguished nerves from tumors with distinct fluorescent signals. These findings demonstrate the potential of NTFP700 as a nerve-targeting fluorophore for local application. The integration of NTFP700 with a tumor-targeting contrast agent, combined with the surgeon-friendly dyed-gauze method, provides a promising strategy for precise nerve and tumor differentiation, potentially reducing the risk of nerve-related complications in oncological procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.